Article and Video CATEGORIES

Cancer Journey

Search By

Chief of Hematology/Oncology and Medical Director at Memorial Cancer Institute, and Clinical Associate Professor of Medicine at Florida International University

Chief of Hematology/Oncology
Medical Director of Memorial Cancer Institute

Lung Cancer Video Library - First Line Immunotherapy for Advanced Non Small Cell Lung Cancer NSCLC
Author
Luis Raez, MD FACP FCCP
Image

 

 

We welcome Dr. Luis Raez, MD FACP FCCP, Chief of Hematology/Oncology and Medical Director at Memorial Cancer Institute, and Clinical Associate Professor of Medicine at Florida International University with 2017 updates to our Lung Cancer Video Library.  In this recent video for GRACE, Dr. Raez discusses First Line Immunotherapy for Advanced Non-Small Cell Lung Cancer NSCLC.

 


 

TRANSCRIPTS 
download here
 

 Dr. Luis Raez, MD FACP FCCP

Chief of Hematology/Oncology and Medical Director, Memorial Cancer Institute
Clinical Associate Professor of Medicine, Florida International University
 

These are very exciting times because we have recently moved immunotherapy to first line, meaning new patients with stage IV non-small cell lung cancer or metastatic patients.   Until recently immunotherapy was approved first for second line and based on some studies - very important - but immunotherapy, after that moved to the front line, so that new patients can have an opportunity to be treated.  Specifically, the Pembrolizumab was moved to the front line based on a study in which the Pembrolizumab was compared against chemotherapy, Carboplatin combination that are the standard of care so far and Pembrolizumab was able to give better outcomes than the combination or amalgamation of chemotherapy but the most important thing in this news is that we are developing markers to try to discover which patients will respond to immunotherapy and which ones will not.  The specific marker that probably everyone knows or cares about is PD-L1.  In this specific study, the patients will benefit from immunotherapy for new patients if the PD-L1 expression in the tumor, we are checking in the tumor, is more than 50%.  Immunotherapy front line was not approved for everybody, it was approved for this specific niche of patient that they will benefit.  The rest of the patients will still need to get chemotherapy or target therapy based on molecular markers if they have any of these genetic alterations that we reference all the time, EGFR, ALK, ROS1.  We only had one drug approved because unfortunately the other drug, Nivolumab, is already approved for second line.  In a similar study, Nivolumab was much against chemotherapy and Nivolumab was unable to get a better progression free survival than the patients on chemotherapy.  For that reason, we only have as a single agent so far, Pembrolizumab, approved in first line.  Of course, there will be changes because we have other immunotherapy agents coming to the market soon and new studies coming soon but so far Pembrolizumab is only approved as a single agent in the front line.  

 


  

Video Language

Next Previous link

Previous PostNext Post

Related Content

Image
Blood Cancer OncTalk
Article
In this series of videos, Dr. Aaron Goodman chairs the discussion along with speakers Drs. Tycel Phillips, Sridevi Rajeeve, Marco Ruiz and Alankrita Taneja.  Topics include:
Article
View the full Targeted Therapies in Lung Cancer Patient forum from 2023 in YouTube and embedded here! 

Forum Discussions

Hello and welcome to Grace.  I'm sorry you're worrying about this but it probably isn't cancer. 

 

From Adenocarcinoma of the lung: from BAC to the future, "GGNs with diameter...

I wanted to share this post with others in your same situation.  This post from Dr. West is the same one I shared in our PM and can hopefully reasure you...

Hi and welcome to Grace.  Wow, I don't know why you can't get in to see your doc but I'd find a way or find another doc who can walk you...

Hi Amber, Welcome to Grace.  I'm so sorry you're going through this scare.  It could be a recurrence.  It also is as likely to be the contrast creating a better view. ...

Hi Blaze,

 

As much as I hate to say it, Welcome back Blaze.  It sounds like you're otherwise feeling good and enjoying life which is a wonderful place to be. ...

Waiting for my appointment with oncologist this morning. Thank you for the response. It helps. <3

Recent Comments

JOIN THE CONVERSATION
Tagrisso is the latest drug…
By JanineT GRACE … on
4th generation of EGFR
By happybluesun on
(At least for the carnivores…
By JanineT GRACE … on
Yes, it is a relief. There…
By blaze100 on